URL,Trial Count,TrialID-Info1,TrialID-Info2,TrialID-Info3,TrialID-Info4,TrialID-Info5,T1-1,T1-1A,T1-2,T1-2A,T1-3,T1-3A,T1-4,T1-4A,T1-5,T1-5A,T1-6,T1-6A,T1-7,T1-7A,T1-8,T1-8A,T1-9,T1-9A,T1-10,T1-10A,Group1,T1-G1-1,T1-G1-1A,T1-G1-2,T1-G1-2A,T1-G1-3,T1-G1-3A,T1-G1-4,T1-G1-4A,T1-G1-5,T1-G1-5A,T1-G1-6,T1-G1-6A,T1-G1-7,T1-G1-7A,T1-G1-8,T1-G1-8A,T1-G1-9,T1-G1-9A,T1-G1-10,T1-G1-10A,T1-G1-11,T1-G1-11A,T1-G1-12,T1-G1-12A,T1-G1-13,T1-G1-13A,T1-G1-14,T1-G1-14A,T1-G1-15,T1-G1-15A,T1-G1-16,T1-G1-16A,T1-G1-17,T1-G1-17A,T1-G1-18,T1-G1-18A,T1-G1-19,T1-G1-19A,T1-G1-20,T1-G1-20A,T1-G1-21,T1-G1-21A,T1-G1-22,T1-G1-22A,T1-G1-23,T1-G1-23A,T1-G1-24,T1-G1-24A,Group2,T1-G2-1,T1-G2-1A,T1-G2-2,T1-G2-2A,T1-G2-3,T1-G2-3A,T1-G2-4,T1-G2-4A,T1-G2-5,T1-G2-5A,T1-G2-6,T1-G2-6A,T1-G2-7,T1-G2-7A,T1-G2-8,T1-G2-8A,T1-G2-9,T1-G2-9A,T1-G2-10,T1-G2-10A,T1-G2-11,T1-G2-11A,T1-G2-12,T1-G2-12A,T1-G2-13,T1-G2-13A,T1-G2-14,T1-G2-14A,T1-G2-15,T1-G2-15A,T1-G2-16,T1-G2-16A,T1-G2-17,T1-G2-17A,T1-G2-18,T1-G2-18A,T1-G2-19,T1-G2-19A,T1-G2-20,T1-G2-20A,T1-G2-21,T1-G2-21A,T1-G2-22,T1-G2-22A,T1-G2-23,T1-G2-23A,T1-G2-24,T1-G2-24A,Group3,T1-G3-1,T1-G3-1A,T1-G3-2,T1-G3-2A,T1-G3-3,T1-G3-3A,T1-G3-4,T1-G3-4A,T1-G3-5,T1-G3-5A,T1-G3-6,T1-G3-6A,T1-G3-7,T1-G3-7A,T1-G3-8,T1-G3-8A,T1-G3-9,T1-G3-9A,T1-G3-10,T1-G3-10A,T1-G3-11,T1-G3-11A,T1-G3-12,T1-G3-12A,T1-G3-13,T1-G3-13A,T1-G3-14,T1-G3-14A,T1-G3-15,T1-G3-15A,T1-G3-16,T1-G3-16A,T1-G3-17,T1-G3-17A,T1-G3-18,T1-G3-18A,T1-G3-19,T1-G3-19A,T1-G3-20,T1-G3-20A,T1-G3-21,T1-G3-21A,T1-G3-22,T1-G3-22A,T1-G3-23,T1-G3-23A,T1-G3-24,T1-G3-24A,Group4,T1-G4-1,T1-G4-1A,T1-G4-2,T1-G4-2A,T1-G4-3,T1-G4-3A,T1-G4-4,T1-G4-4A,T1-G4-5,T1-G4-5A,T1-G4-6,T1-G4-6A,T1-G4-7,T1-G4-7A,T1-G4-8,T1-G4-8A,T1-G4-9,T1-G4-9A,T1-G4-10,T1-G4-10A,T1-G4-11,T1-G4-11A,T1-G4-12,T1-G4-12A,T1-G4-13,T1-G4-13A,T1-G4-14,T1-G4-14A,T1-G4-15,T1-G4-15A,T1-G4-16,T1-G4-16A,T1-G4-17,T1-G4-17A,T1-G4-18,T1-G4-18A,T1-G4-19,T1-G4-19A,T1-G4-20,T1-G4-20A,T1-G4-21,T1-G4-21A,T1-G4-22,T1-G4-22A,T1-G4-23,T1-G4-23A,T1-G4-24,T1-G4-24A,Group5,T1-G5-1,T1-G5-1A,T1-G5-2,T1-G5-2A,T1-G5-3,T1-G5-3A,T1-G5-4,T1-G5-4A,T1-G5-5,T1-G5-5A,T1-G5-6,T1-G5-6A,T1-G5-7,T1-G5-7A,T1-G5-8,T1-G5-8A,T1-G5-9,T1-G5-9A,T1-G5-10,T1-G5-10A,T1-G5-11,T1-G5-11A,T1-G5-12,T1-G5-12A,T1-G5-13,T1-G5-13A,T1-G5-14,T1-G5-14A,T1-G5-15,T1-G5-15A,T1-G5-16,T1-G5-16A,T1-G5-17,T1-G5-17A,T1-G5-18,T1-G5-18A,T1-G5-19,T1-G5-19A,T1-G5-20,T1-G5-20A,T1-G5-21,T1-G5-21A,T1-G5-22,T1-G5-22A,T1-G5-23,T1-G5-23A,T1-G5-24,T1-G5-24A,Group6,T1-G6-1,T1-G6-1A,T1-G6-2,T1-G6-2A,T1-G6-3,T1-G6-3A,T1-G6-4,T1-G6-4A,T1-G6-5,T1-G6-5A,T1-G6-6,T1-G6-6A,T1-G6-7,T1-G6-7A,T1-G6-8,T1-G6-8A,T1-G6-9,T1-G6-9A,T1-G6-10,T1-G6-10A,T1-G6-11,T1-G6-11A,T1-G6-12,T1-G6-12A,T1-G6-13,T1-G6-13A,T1-G6-14,T1-G6-14A,T1-G6-15,T1-G6-15A,T1-G6-16,T1-G6-16A,T1-G6-17,T1-G6-17A,T1-G6-18,T1-G6-18A,T1-G6-19,T1-G6-19A,T1-G6-20,T1-G6-20A,T1-G6-21,T1-G6-21A,T1-G6-22,T1-G6-22A,T1-G6-23,T1-G6-23A,T1-G6-24,T1-G6-24A,Group7,T1-G7-1,T1-G7-1A,T1-G7-2,T1-G7-2A,T1-G7-3,T1-G7-3A,T1-G7-4,T1-G7-4A,T1-G7-5,T1-G7-5A,T1-G7-6,T1-G7-6A,T1-G7-7,T1-G7-7A,T1-G7-8,T1-G7-8A,T1-G7-9,T1-G7-9A,T1-G7-10,T1-G7-10A,T1-G7-11,T1-G7-11A,T1-G7-12,T1-G7-12A,T1-G7-13,T1-G7-13A,T1-G7-14,T1-G7-14A,T1-G7-15,T1-G7-15A,T1-G7-16,T1-G7-16A,T1-G7-17,T1-G7-17A,T1-G7-18,T1-G7-18A,T1-G7-19,T1-G7-19A,T1-G7-20,T1-G7-20A,T1-G7-21,T1-G7-21A,T1-G7-22,T1-G7-22A,T1-G7-23,T1-G7-23A,T1-G7-24,T1-G7-24A,Group8,T1-G8-1,T1-G8-1A,T1-G8-2,T1-G8-2A,T1-G8-3,T1-G8-3A,T1-G8-4,T1-G8-4A,T1-G8-5,T1-G8-5A,T1-G8-6,T1-G8-6A,T1-G8-7,T1-G8-7A,T1-G8-8,T1-G8-8A,T1-G8-9,T1-G8-9A,T1-G8-10,T1-G8-10A,T1-G8-11,T1-G8-11A,T1-G8-12,T1-G8-12A,T1-G8-13,T1-G8-13A,T1-G8-14,T1-G8-14A,T1-G8-15,T1-G8-15A,T1-G8-16,T1-G8-16A,T1-G8-17,T1-G8-17A,T1-G8-18,T1-G8-18A,T1-G8-19,T1-G8-19A,T1-G8-20,T1-G8-20A,T1-G8-21,T1-G8-21A,T1-G8-22,T1-G8-22A,T1-G8-23,T1-G8-23A,T1-G8-24,T1-G8-24A,Group9,T1-G9-1,T1-G9-1A,T1-G9-2,T1-G9-2A,T1-G9-3,T1-G9-3A,T1-G9-4,T1-G9-4A,T1-G9-5,T1-G9-5A,T1-G9-6,T1-G9-6A,T1-G9-7,T1-G9-7A,T1-G9-8,T1-G9-8A,T1-G9-9,T1-G9-9A,T1-G9-10,T1-G9-10A,T1-G9-11,T1-G9-11A,T1-G9-12,T1-G9-12A,T1-G9-13,T1-G9-13A,T1-G9-14,T1-G9-14A,T1-G9-15,T1-G9-15A,T1-G9-16,T1-G9-16A,T1-G9-17,T1-G9-17A,T1-G9-18,T1-G9-18A,T1-G9-19,T1-G9-19A,T1-G9-20,T1-G9-20A,T1-G9-21,T1-G9-21A,T1-G9-22,T1-G9-22A,T1-G9-23,T1-G9-23A,T1-G9-24,T1-G9-24A,Group10,T1-G10-1,T1-G10-1A,T1-G10-2,T1-G10-2A,T1-G10-3,T1-G10-3A,T1-G10-4,T1-G10-4A,T1-G10-5,T1-G10-5A,T1-G10-6,T1-G10-6A,T1-G10-7,T1-G10-7A,T1-G10-8,T1-G10-8A,T1-G10-9,T1-G10-9A,T1-G10-10,T1-G10-10A,T1-G10-11,T1-G10-11A,T1-G10-12,T1-G10-12A,T1-G10-13,T1-G10-13A,T1-G10-14,T1-G10-14A,T1-G10-15,T1-G10-15A,T1-G10-16,T1-G10-16A,T1-G10-17,T1-G10-17A,T1-G10-18,T1-G10-18A,T1-G10-19,T1-G10-19A,T1-G10-20,T1-G10-20A,T1-G10-21,T1-G10-21A,T1-G10-22,T1-G10-22A,T1-G10-23,T1-G10-23A,T1-G10-24,T1-G10-24A,Group11,T1-G11-1,T1-G11-1A,T1-G11-2,T1-G11-2A,T1-G11-3,T1-G11-3A,T1-G11-4,T1-G11-4A,T1-G11-5,T1-G11-5A,T1-G11-6,T1-G11-6A,T1-G11-7,T1-G11-7A,T1-G11-8,T1-G11-8A,T1-G11-9,T1-G11-9A,T1-G11-10,T1-G11-10A,T1-G11-11,T1-G11-11A,T1-G11-12,T1-G11-12A,T1-G11-13,T1-G11-13A,T1-G11-14,T1-G11-14A,T1-G11-15,T1-G11-15A,T1-G11-16,T1-G11-16A,T1-G11-17,T1-G11-17A,T1-G11-18,T1-G11-18A,T1-G11-19,T1-G11-19A,T1-G11-20,T1-G11-20A,T1-G11-21,T1-G11-21A,T1-G11-22,T1-G11-22A,T1-G11-23,T1-G11-23A,T1-G11-24,T1-G11-24A,Group12,T1-G12-1,T1-G12-1A,T1-G12-2,T1-G12-2A,T1-G12-3,T1-G12-3A,T1-G12-4,T1-G12-4A,T1-G12-5,T1-G12-5A,T1-G12-6,T1-G12-6A,T1-G12-7,T1-G12-7A,T1-G12-8,T1-G12-8A,T1-G12-9,T1-G12-9A,T1-G12-10,T1-G12-10A,T1-G12-11,T1-G12-11A,T1-G12-12,T1-G12-12A,T1-G12-13,T1-G12-13A,T1-G12-14,T1-G12-14A,T1-G12-15,T1-G12-15A,T1-G12-16,T1-G12-16A,T1-G12-17,T1-G12-17A,T1-G12-18,T1-G12-18A,T1-G12-19,T1-G12-19A,T1-G12-20,T1-G12-20A,T1-G12-21,T1-G12-21A,T1-G12-22,T1-G12-22A,T1-G12-23,T1-G12-23A,T1-G12-24,T1-G12-24A
https://pubmed.ncbi.nlm.nih.gov/39212199/,1,N/A:Cosmetic Suturing Skills Study:23,,,,,What is the NCT# Associated with this clinical trial? (If there is one),N/A,"What Phase is the clinical trial in? Phase 1, Phase 2, Phase 3, or Phase 4?",N/A,"What type of cancer(s) was this trial studying? ie- NSCLC, SCLC, Melanoma, Leukemia, Colon etc",N/A,Describe the Cancer Type?,N/A,Who sponsored the clinical trial?,N/A,What were the novel findings of this trial?,Spaced learning improves short-term acquisition and long-term retention of cosmetic suturing skills.,What conclusions were reached regarding this clinical trial?,Incorporating spaced learning into instructional process enhances short-term skill improvement and long-term retention of training outcomes.,Is there any other relevant information that might make this clinical trial unique?,This trial was conducted in surgical residents and evaluated the effectiveness of spaced learning in complex surgical procedures.,Were there any subgroups in this study that the clinical trial identified had heightened responses to the intervention?,N/A,,,ControlGroup:Concentrated Training:Continuous 3-hour training,Is this the control group or the intervention group?,Control group,What drug(s) was the clinical trial studying in the this group/cohort?,N/A,What was the Treatment ORR in this group/cohort?,N/A,What was the Intervention Treatment PFS in this group/cohort?,N/A,What was the Intervention Treatment OS in this group/cohort?,N/A,What percentage of patients In the intervention group discontinued?,N/A,Did the Group Specifically meet it’s endpoints? Yes or No or NA,N/A,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",N/A,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",N/A,Did the Group Specifically include patients who had previously taken a specific drug type?,N/A,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",N/A,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",N/A,Did the Group Specifically include patients who had brain brain metastases? Yes or No,N/A,Did the Group Specifically include patients who had previous surgery? Yes or No,N/A,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,N/A,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,N/A,Did the Group Specifically include patients who were previously untreated?,N/A,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",N/A,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",N/A,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",N/A,Was the treatment for this group well tolerated?,N/A,Were the specific adverse reactions associated with this group?,N/A,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",N/A,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X",N/A,InterventionGroup:Spaced Training:40 minutes of training followed by a 20-minute break,Is this the control group or the intervention group?,Intervention group,What drug(s) was the clinical trial studying in the this group/cohort?,N/A,What was the Treatment ORR in this group/cohort?,N/A,What was the Intervention Treatment PFS in this group/cohort?,N/A,What was the Intervention Treatment OS in this group/cohort?,N/A,What percentage of patients In the intervention group discontinued?,N/A,Did the Group Specifically meet it’s endpoints? Yes or No or NA,Yes,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",N/A,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",N/A,Did the Group Specifically include patients who had previously taken a specific drug type?,N/A,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",N/A,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",N/A,Did the Group Specifically include patients who had brain brain metastases? Yes or No,N/A,Did the Group Specifically include patients who had previous surgery? Yes or No,N/A,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,N/A,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,N/A,Did the Group Specifically include patients who were previously untreated?,N/A,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",N/A,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",N/A,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",N/A,Was the treatment for this group well tolerated?,N/A,Were the specific adverse reactions associated with this group?,N/A,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",N/A,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X","Suture technique score: 28.46 ± 1.78, Suture quality score: 32.26 ± 4.01, Suturing time score: 14.67 ± 1.15",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/39191066/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/38760920/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/39314097/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/39168032/,1,NCT#:Not Provided:Non-bespoke three-dimensional simulation of the aesthetic outcome for breast conserving treatment:117,,,,,What is the NCT# Associated with this clinical trial? (If there is one),Not Provided,"What Phase is the clinical trial in? Phase 1, Phase 2, Phase 3, or Phase 4?",Not Provided,"What type of cancer(s) was this trial studying? ie- NSCLC, SCLC, Melanoma, Leukemia, Colon etc",Breast Cancer,Describe the Cancer Type?,Not Provided,Who sponsored the clinical trial?,Not Provided,What were the novel findings of this trial?,The use of a non-bespoke three-dimensional simulation of the aesthetic outcome for breast conserving treatment in the preoperative setting does not over-inflate expectations compared to standard care.,What conclusions were reached regarding this clinical trial?,"Viewing their own 3D-SI standardised simulation did not significantly affect how the participants perceived their aesthetic outcome. In addition, it did not alter the patient-reported satisfaction.",Is there any other relevant information that might make this clinical trial unique? (Try to keep this somewhat concise),"The trial used 3D-simulation, viewing post-operative 2D photographs of other women, and standard care to inform patients about aesthetic outcomes.",Were there any subgroups in this study that the clinical trial identified had heightened responses to the intervention?,NA,,,Standard Care:Verbal description only:No simulation or photographs,Is this the control group or the intervention group?,Control group,What drug(s) was the clinical trial studying in the this group/cohort?,NA,What was the Treatment ORR in this group/cohort?,NA,What was the Intervention Treatment PFS in this group/cohort?,NA,What was the Intervention Treatment OS in this group/cohort?,NA,What percentage of patients In the intervention group discontinued?,NA,Did the Group Specifically meet it’s endpoints? Yes or No or NA,NA,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",NA,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",NA,Did the Group Specifically include patients who had previously taken a specific drug type?,NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",NA,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Yes,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,NA,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,NA,Did the Group Specifically include patients who were previously untreated?,NA,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",NA,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",NA,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",NA,Was the treatment for this group well tolerated?,NA,Were the specific adverse reactions associated with this group?,NA,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",NA,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X",NA,Intervention Group:2D photographs of other women:Viewing post-operative photographs,Is this the control group or the intervention group?,Intervention group,What drug(s) was the clinical trial studying in the this group/cohort?,NA,What was the Treatment ORR in this group/cohort?,NA,What was the Intervention Treatment PFS in this group/cohort?,NA,What was the Intervention Treatment OS in this group/cohort?,NA,What percentage of patients In the intervention group discontinued?,NA,Did the Group Specifically meet it’s endpoints? Yes or No or NA,NA,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",NA,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",NA,Did the Group Specifically include patients who had previously taken a specific drug type?,NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",NA,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Yes,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,NA,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,NA,Did the Group Specifically include patients who were previously untreated?,NA,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",NA,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",NA,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",NA,Was the treatment for this group well tolerated?,NA,Were the specific adverse reactions associated with this group?,NA,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",NA,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X",NA,Intervention Group:3D-SI simulation:Standardised preoperative 3D-SI simulation,Is this the control group or the intervention group?,Intervention group,What drug(s) was the clinical trial studying in the this group/cohort?,NA,What was the Treatment ORR in this group/cohort?,NA,What was the Intervention Treatment PFS in this group/cohort?,NA,What was the Intervention Treatment OS in this group/cohort?,NA,What percentage of patients In the intervention group discontinued?,NA,Did the Group Specifically meet it’s endpoints? Yes or No or NA,NA,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",NA,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",NA,Did the Group Specifically include patients who had previously taken a specific drug type?,NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",NA,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Yes,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,NA,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,NA,Did the Group Specifically include patients who were previously untreated?,NA,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",NA,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",NA,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",NA,Was the treatment for this group well tolerated?,NA,Were the specific adverse reactions associated with this group?,NA,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",NA,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X",NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/39069436/,1,NCT#:Not Provided:ZRC-3277 vs Perjeta for HER2-positive MBC:268,,,,,What is the NCT# Associated with this clinical trial? (If there is one),Not Provided,"What Phase is the clinical trial in? Phase 1, Phase 2, Phase 3, or Phase 4?",Phase 3,"What type of cancer(s) was this trial studying? ie- NSCLC, SCLC, Melanoma, Leukemia, Colon etc",Metastatic Breast Cancer (MBC),Describe the Cancer Type?,HER2-positive MBC,Who sponsored the clinical trial?,Not Provided,What were the novel findings of this trial?,Noninferiority of ZRC-3277 to Perjeta in terms of ORR,What conclusions were reached regarding this clinical trial?,"Efficacy, PK, immunogenicity, and safety profiles of ZRC-3277 were similar to those of Perjeta",Is there any other relevant information that might make this clinical trial unique? (Try to keep this somewhat concise),This is a biosimilar study,Were there any subgroups in this study that the clinical trial identified had heightened responses to the intervention?,NA,,,"ZRC-3277 Group:ZRC-3277, trastuzumab, docetaxel:HER2-positive MBC",Is this the control group or the intervention group?,Intervention group,What drug(s) was the clinical trial studying in the this group/cohort?,"ZRC-3277, trastuzumab, docetaxel",What was the Treatment ORR in this group/cohort?,87.39%,What was the Intervention Treatment PFS in this group/cohort?,NA,What was the Intervention Treatment OS in this group/cohort?,NA,What percentage of patients In the intervention group discontinued?,NA,Did the Group Specifically meet it’s endpoints? Yes or No or NA,Yes,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Metastatic,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",HER2,Did the Group Specifically include patients who had previously taken a specific drug type?,No,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",NA,Did the Group Specifically include patients who had brain brain metastases? Yes or No,NA,Did the Group Specifically include patients who had previous surgery? Yes or No,NA,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,Yes,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,Yes,Did the Group Specifically include patients who were previously untreated?,Yes,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",NA,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",NA,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",1st line,Was the treatment for this group well tolerated?,Yes,Were the specific adverse reactions associated with this group?,NA,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",NA,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X",NA,"Perjeta Group:Perjeta, trastuzumab, docetaxel:HER2-positive MBC",Is this the control group or the intervention group?,Control group,What drug(s) was the clinical trial studying in the this group/cohort?,"Perjeta, trastuzumab, docetaxel",What was the Treatment ORR in this group/cohort?,91.94%,What was the Intervention Treatment PFS in this group/cohort?,NA,What was the Intervention Treatment OS in this group/cohort?,NA,What percentage of patients In the intervention group discontinued?,NA,Did the Group Specifically meet it’s endpoints? Yes or No or NA,Yes,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Metastatic,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",HER2,Did the Group Specifically include patients who had previously taken a specific drug type?,No,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",NA,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",NA,Did the Group Specifically include patients who had brain brain metastases? Yes or No,NA,Did the Group Specifically include patients who had previous surgery? Yes or No,NA,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,Yes,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,Yes,Did the Group Specifically include patients who were previously untreated?,Yes,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",NA,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",NA,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",1st line,Was the treatment for this group well tolerated?,Yes,Were the specific adverse reactions associated with this group?,NA,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",Yes,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X",NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/38959996/,1,NCT#:Not Provided:Patient Navigation Program in Children with CKD:162,,,,,What is the NCT# Associated with this clinical trial? (If there is one),Not Provided,"What Phase is the clinical trial in? Phase 1, Phase 2, Phase 3, or Phase 4?",Not Provided,"What type of cancer(s) was this trial studying? ie- NSCLC, SCLC, Melanoma, Leukemia, Colon etc",Not Applicable (Chronic Kidney Disease),Describe the Cancer Type?,Not Applicable (Chronic Kidney Disease),Who sponsored the clinical trial?,Not Provided,What were the novel findings of this trial?,"Patient navigation program does not improve self-rated health in children with CKD, but caregivers gained skills related to providing and accessing care.",What conclusions were reached regarding this clinical trial?,"Patient navigation program may not be effective in improving health outcomes for children with CKD, but may have benefits for caregivers.",Is there any other relevant information that might make this clinical trial unique? (Try to keep this somewhat concise),The trial focused on children from low socioeconomic status backgrounds and/or residing in remote areas.,Were there any subgroups in this study that the clinical trial identified had heightened responses to the intervention?,No,,,Immediate Group:Patient Navigation Program:Received patient navigation at randomization,Is this the control group or the intervention group?,Intervention Group,What drug(s) was the clinical trial studying in the this group/cohort?,Not Applicable (Patient Navigation Program),What was the Treatment ORR in this group/cohort?,Not Applicable,What was the Intervention Treatment PFS in this group/cohort?,Not Applicable,What was the Intervention Treatment OS in this group/cohort?,Not Applicable,What percentage of patients In the intervention group discontinued?,Not Provided,Did the Group Specifically meet it’s endpoints? Yes or No or NA,No,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Not Applicable (Chronic Kidney Disease),"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",No,Did the Group Specifically include patients who had previously taken a specific drug type?,No,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",No,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so, List the drug types",No,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Not Provided,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,Not Applicable (Chronic Kidney Disease),Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,Not Applicable (Chronic Kidney Disease),Did the Group Specifically include patients who were previously untreated?,Not Provided,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",No,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",No,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",Not Provided,Was the treatment for this group well tolerated?,Not Applicable (Patient Navigation Program),Were the specific adverse reactions associated with this group?,No,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",Not Applicable (Patient Navigation Program),"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X","SRH, caregivers' SRH and satisfaction with health care, children's quality of life, hospitalizations, and missed school days",Waitlist Group:Patient Navigation Program:Received patient navigation at six months,Is this the control group or the intervention group?,Waitlist Group (Control Group),What drug(s) was the clinical trial studying in the this group/cohort?,Not Applicable (Patient Navigation Program),What was the Treatment ORR in this group/cohort?,Not Applicable,What was the Intervention Treatment PFS in this group/cohort?,Not Applicable,What was the Intervention Treatment OS in this group/cohort?,Not Applicable,What percentage of patients In the intervention group discontinued?,Not Provided,Did the Group Specifically meet it’s endpoints? Yes or No or NA,No,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Not Applicable (Chronic Kidney Disease),"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",No,Did the Group Specifically include patients who had previously taken a specific drug type?,No,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",No,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so, List the drug types",No,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Not Provided,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,Not Applicable (Chronic Kidney Disease),Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,Not Applicable (Chronic Kidney Disease),Did the Group Specifically include patients who were previously untreated?,Not Provided,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",No,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",No,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",Not Provided,Was the treatment for this group well tolerated?,Not Applicable (Patient Navigation Program),Were the specific adverse reactions associated with this group?,No,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",Not Applicable (Patient Navigation Program),"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X","SRH, caregivers' SRH and satisfaction with health care, children's quality of life, hospitalizations, and missed school days",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/38918160/,1,NCT#:Not Provided:S-ketamine Trial:72,,,,,What is the NCT# Associated with this clinical trial? (If there is one),Not Provided,"What Phase is the clinical trial in? Phase 1, Phase 2, Phase 3, or Phase 4?",Not Provided,"What type of cancer(s) was this trial studying? ie- NSCLC, SCLC, Melanoma, Leukemia, Colon etc",Breast Cancer,Describe the Cancer Type?,Not Provided,Who sponsored the clinical trial?,Not Provided,What were the novel findings of this trial?,S-ketamine infusion reduces the incidence of CPSP 3 months after breast surgery.,What conclusions were reached regarding this clinical trial?,S-ketamine infusion reduces the incidence of CPSP 3 months after breast surgery.,Is there any other relevant information that might make this clinical trial unique?,The trial focused on chronic postoperative surgical pain (CPSP) after breast surgery.,Were there any subgroups in this study that the clinical trial identified had heightened responses to the intervention?,No,,,ControlGroup:Placebo:0.9% saline,Is this the control group or the intervention group?,Control Group,What drug(s) was the clinical trial studying in the this group/cohort?,Placebo (0.9% saline),What was the Treatment ORR in this group/cohort?,Not Provided,What was the Intervention Treatment PFS in this group/cohort?,Not Provided,What was the Intervention Treatment OS in this group/cohort?,Not Provided,What percentage of patients In the intervention group discontinued?,Not Provided,Did the Group Specifically meet it’s endpoints? Yes or No or NA,NA,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Not Provided,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",No,Did the Group Specifically include patients who had previously taken a specific drug type?,No,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",No,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",No,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Yes,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,No,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,No,Did the Group Specifically include patients who were previously untreated?,Yes,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",No,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",No,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",Not Provided,Was the treatment for this group well tolerated?,Not Provided,Were the specific adverse reactions associated with this group?,Not Provided,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",NA,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X","NRS scores, PHQ-9 scores",InterventionGroup:S-ketamine:1.5 mg kg-1 bolus followed by 2 mg kg-1h-1 infusion,Is this the control group or the intervention group?,Intervention Group,What drug(s) was the clinical trial studying in the this group/cohort?,S-ketamine,What was the Treatment ORR in this group/cohort?,Not Provided,What was the Intervention Treatment PFS in this group/cohort?,Not Provided,What was the Intervention Treatment OS in this group/cohort?,Not Provided,What percentage of patients In the intervention group discontinued?,Not Provided,Did the Group Specifically meet it’s endpoints? Yes or No or NA,Yes,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Not Provided,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",No,Did the Group Specifically include patients who had previously taken a specific drug type?,No,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",No,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",No,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Yes,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,No,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,No,Did the Group Specifically include patients who were previously untreated?,Yes,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",No,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",No,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",Not Provided,Was the treatment for this group well tolerated?,Not Provided,Were the specific adverse reactions associated with this group?,Not Provided,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",NA,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X","NRS scores, PHQ-9 scores, CPSP incidence",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/38897316/,1,NCT#:Not Provided:Not Provided:628,,,,,What is the NCT# Associated with this clinical trial? (If there is one),Not Provided,"What Phase is the clinical trial in? Phase 1, Phase 2, Phase 3, or Phase 4?",Phase 3,"What type of cancer(s) was this trial studying? ie- NSCLC, SCLC, Melanoma, Leukemia, Colon etc",Breast Cancer,Describe the Cancer Type?,Not Provided,Who sponsored the clinical trial?,Not Provided,What were the novel findings of this trial?,The lower pre-RT PLC predicted poorer survival.,What conclusions were reached regarding this clinical trial?,Radiation-induced lymphopenia in patients with breast cancer after BCS tends to be mild.,Is there any other relevant information that might make this clinical trial unique? (Try to keep this somewhat concise),The trial compared hypofractionated RT (HFRT) with conventional fractionated RT (CFRT) after BCS.,Were there any subgroups in this study that the clinical trial identified had heightened responses to the intervention?,Not Provided,,,ControlGroup:Conventional Fractionated RT (CFRT):Received conventional fractionated RT (CFRT) after BCS,Is this the control group or the intervention group?,Control Group,What drug(s) was the clinical trial studying in the this group/cohort?,Not Provided,What was the Treatment ORR in this group/cohort?,Not Provided,What was the Intervention Treatment PFS in this group/cohort?,Not Provided,What was the Intervention Treatment OS in this group/cohort?,Not Provided,What percentage of patients In the intervention group discontinued?,Not Provided,Did the Group Specifically meet it’s endpoints? Yes or No or NA,Not Provided,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Not Provided,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",Not Provided,Did the Group Specifically include patients who had previously taken a specific drug type?,Not Provided,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",Not Provided,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",Not Provided,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Yes,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,Not Provided,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,Not Provided,Did the Group Specifically include patients who were previously untreated?,Not Provided,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",Not Provided,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",Not Provided,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",Not Provided,Was the treatment for this group well tolerated?,Not Provided,Were the specific adverse reactions associated with this group?,Lymphopenia,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",Not Provided,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X","BCSS, OS",InterventionGroup:Hypofractionated RT (HFRT):Received hypofractionated RT (HFRT) after BCS,Is this the control group or the intervention group?,Intervention Group,What drug(s) was the clinical trial studying in the this group/cohort?,Not Provided,What was the Treatment ORR in this group/cohort?,Not Provided,What was the Intervention Treatment PFS in this group/cohort?,Not Provided,What was the Intervention Treatment OS in this group/cohort?,Not Provided,What percentage of patients In the intervention group discontinued?,Not Provided,Did the Group Specifically meet it’s endpoints? Yes or No or NA,Not Provided,"Did the Group Specifically include patients who had specific stages of cancer? If so, what stages?",Not Provided,"Did the Group include patients who had targets? (such as mutations, biomarkers, genes, etc)",Not Provided,Did the Group Specifically include patients who had previously taken a specific drug type?,Not Provided,"Did the Group Specifically include patients who had specifically developed resistance to specific drugs? If so, List the drugs",Not Provided,"Did the Group Specifically include patients who had specifically developed resistance to specific drug types? If so,  List the drug types",Not Provided,Did the Group Specifically include patients who had brain brain metastases? Yes or No,No,Did the Group Specifically include patients who had previous surgery? Yes or No,Yes,Did the Group Specifically include patients who had “advanced” cancer? Yes or No,Not Provided,Did the Group Specifically include patients who had “metastatic” cancer? Yes or No,Not Provided,Did the Group Specifically include patients who were previously untreated?,Not Provided,"Did the Group Specifically include patients who had previously taken a specific drug? If so, List the drugs",Not Provided,"Did the Group Specifically include patients who had NOT previously taken a specific drug? If so, List the drugs",Not Provided,"Did the Group specifically include patients who were receiving a 1st,2nd,3rd,4th,5th… Therapy? Please Specify",Not Provided,Was the treatment for this group well tolerated?,Not Provided,Were the specific adverse reactions associated with this group?,Lymphopenia,"Has the intervention drug(s) for this group been approved? Yes, No, or NA",Not Provided,"What other efficacy data points were measured? (ie- TTP, DoR, CR, PR, SD, CBR, pCR etc) Give in the format TTP:X, DoR:X, CR:X","BCSS, OS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/38777932/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
https://pubmed.ncbi.nlm.nih.gov/38714424/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,